Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Open accessThe DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with idiopathic pulmonary fibrosis in a 1:1:1 ratio to receive nerandomilast at a dose of 18 mg twice daily, nerandomilast at a dose of 9 mg twice daily, or placebo, with stratification according to background antifibrotic therapy (nintedanib or pirfenidone vs. none). The primary end point was the absolute change from baseline in forced vital capacity (FVC), measured in milliliters, at week 52. RESULTS: A total of 1177 patients underwent randomization, of whom 77.7% were taking nintedanib or pirfenidone at enrollment. Adjusted mean changes in FVC at week 52 were -114.7 ml (95% confidence interval [CI], -141.8 to -87.5) in the nerandomilast 18-mg group, -138.6 ml (95% CI, -165.6 to -111.6) in the nerandomilast 9-mg group, and -183.5 ml (95% CI, -210.9 to -156.1) in the placebo group. The adjusted difference between the nerandomilast 18-mg group and the placebo group was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001), and the adjusted difference between the nerandomilast 9-mg group and the placebo group was 44.9 ml (95% CI, 6.4 to 83.3; P = 0.02). The most frequent adverse event in the nerandomilast groups was diarrhea, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, as compared with 16.0% in the placebo group. Serious adverse events were balanced across trial groups. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, treatment with nerandomilast resulted in a smaller decline in the FVC than placebo over a period of 52 weeks. (Funded by Boehringer Ingelheim; FIBRONEER-IPF ClinicalTrials.gov number, NCT05321069.).
Overview
CoChat Summary
TL;DR
In this phase 3, double-blind trial, nerandomilast (BI 1015550), an oral preferential phosphodiesterase 4B inhibitor, reduced the 52-week decline in forced vital capacity compared with placebo in patients with idiopathic pulmonary fibrosis. Both the 18-mg and 9-mg twice-daily doses were superior to placebo, with diarrhea the most frequent adverse event.
Key findings
- Adjusted mean change in FVC at week 52 was −114.7 ml (95% CI, −141.8 to −87.5) with nerandomilast 18 mg, −138.6 ml (95% CI, −165.6 to −111.6) with nerandomilast 9 mg, and −183.5 ml (95% CI, −210.9 to −156.1) with placebo.
- Adjusted difference versus placebo was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001) for the 18-mg dose and 44.9 ml (95% CI, 6.4 to 83.3; P=0.02) for the 9-mg dose.
- Diarrhea was the most frequent adverse event in the nerandomilast groups: 41.3% (18 mg) and 31.1% (9 mg) versus 16.0% with placebo; serious adverse events were balanced across trial groups.
- Of 1177 randomized patients, 77.7% were taking nintedanib or pirfenidone at enrollment.
Methods
- Phase 3, double-blind trial; patients with idiopathic pulmonary fibrosis were randomly assigned 1:1:1 to nerandomilast 18 mg twice daily, nerandomilast 9 mg twice daily, or placebo.
- Randomization was stratified according to background antifibrotic therapy (nintedanib or pirfenidone vs. none).
- Primary end point: absolute change from baseline in FVC (milliliters) at week 52; 1177 patients underwent randomization. (Funded by Boehringer Ingelheim; FIBRONEER-IPF, NCT05321069.)
Limitations
- Not stated in the paper (the provided text is the structured abstract and does not report a limitations section).
- Evident from the text: only the primary end point and the most frequent adverse event are reported here, with no detail on secondary outcomes, subgroup analyses, or the full safety profile; the abstract also does not report patient baseline characteristics or trial duration beyond the 52-week end point.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 12 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the adjusted difference between the nerandomilast 9-mg group and the placebo group was 44.9 ml (95% CI, 6.4 to 83.3; P = 0.02)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“-183.5 ml (95% CI, -210.9 to -156.1) in the placebo group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted difference between the nerandomilast 18-mg group and the placebo group was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adjusted mean changes in FVC at week 52 were -114.7 ml (95% confidence interval [CI], -141.8 to -87.5) in the nerandomilast 18-mg group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most frequent adverse event in the nerandomilast groups was diarrhea, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, as compared with 16.0% in the placebo group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
3 more claims
Create a free account to see all 13 claims and every source verdict.
- Borderline: one of the tests for a substantial claim is unclear. 1
- Probably not a substantial claim. 3
- It may state two separate claims as one. 2
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The approved anti-fibrotic drugs nintedanib (Ofev®), pirfenidone (Esbriet®), and nerandomilast (Jascayd®) slow the rate of FVC decline2,4, but do not halt disease progression or restore lung function.”
From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [4]
Experimental — accuracy not yet measured
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationGraham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., Hallstrand, T. S., Kaminsky, D. A., McCarthy, K., McCormack, M. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1590st · Cited by 4,305
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationStandardisation of the single-breath determination of carbon monoxide uptake in the lung
MacIntyre, N., Crapo, R. O., Viegi, G., Johnson, D. C., van der Grinten, C. P. M., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034905 · Cited by 2,255
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationA graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236
Self-citationThe leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., & Pardo, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109482 · Cited by 225
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503643 · Cited by 205
Self-citation
Cited by
Items 101–200 of 239
Medikamentöse Fibrosehemmung am Beispiel der systemischen Sklerose: Möglichkeiten und Grenzen
Dashi, T., & Bergmann, C. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01925-1
A Year in Review from the American Thoracic Society (ATS) 2025 International Conference
Eggleston, R. H. (2025) · Respiratory The American Medical Journal · doi:10.33590/respiramj/rhyt2481
Von elektronischen Spürnasen und molekularen „Snipern“
Bach, B. (2025) · Pneumo News · doi:10.1007/s15033-025-4218-8
Pneumopathies interstitielles diffuses : avancées et perspectives thérapeutiques
Jeny, F. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00041-2
Hedgehog signalling: on the way to curing idiopathic pulmonary fibrosis
Spagnolo, P., & Khor, Y. H. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00284-x
Clark, K. P., & Kass, D. J. (2025) · Thorax · doi:10.1136/thorax-2025-223656
Metformina: paradigma de pleiotropismo terapéutico (1922-2025)
de Leiva, A., & Morell, F. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107189
The cyclic AMP paradox in pulmonary fibrosis: context is everything…
Selvarajah, B., & Scotton, C. J. (2025) · European Respiratory Journal · doi:10.1183/13993003.01382-2025
Metformin: Paradigm of therapeutic pleiotropism (1922–2025)
de Leiva, A., & Morell, F. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107189 · Cited by 1
Targeted Therapy for Interstitial Lung Disease and the Role of Nerandomilast
Moir, H., & Jinks, J. (2025) · EMJ Respiratory · doi:10.33590/emjrespir/nuyd2874
Was bringt die Kombination von Antifibrotika?
von Grätz, P. G. (2025) · Pneumo News · doi:10.1007/s15033-025-4252-6
Dynamic Chest Radiography versus Pulmonary Function Tests in Chronic Obstructive Pulmonary Disease
Hatabu, H., Kudoh, S., & Frendl, G. (2025) · Radiology · doi:10.1148/radiol.253426
Kim, S., Park, J. Y., Cho, Y. L., & Kang, W. J. (2025) · Diagnostics · doi:10.3390/diagnostics16010010 · Cited by 1
“These advances highlight the continued need for imaging biomarkers capable of assessing fibrotic activity and treatment response [4,5].”
Progressive Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases
Iwasawa, T., Baba, T., & Ogura, T. (2025) · Haigan · doi:10.2482/haigan.65.887
Idiopathische Lungenfibrose: Nerandomilast verlangsamt Lungenfunktionsverlust
Simon, A. (2025) · Pneumologie · doi:10.1055/a-2645-6332
Branz, A., Shalashova, I., Funk, A. M., Gensheimer, T., Wytyk, A., Wespel, S. L., Drescher, J., Mayr, C. H., Neubert, L., Kamp, J. C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8256899/v1
Shared genetic architecture across fibrotic diseases
Bundgaard, J. S., Rand, S. A., Bentsen, M. S., Pedersen, O. B., Sørensen, E., Erikstrup, C., Bruun, M. T., Aagaard, B., Larsen, O. H., Dyrskjøt, L., et al. (2026) · Nature Communications · doi:10.21203/rs.3.rs-8156241/v1
Carolan, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-025-00452-z
“There are new therapeutic options showing promise, such as nerandomilast, an inhibitor of phosphodiesterase 4B [ 13].”
Fibroneer Trials: More than Meets the Eye
Teo, F. S. W., & Song, J. W. (2026) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2025.0186
“…3, double-blind trial, involving 1,177 patients with IPF randomized in a 1:1:1 ratio to receive nerandomilast at a dose of 18 mg twice daily, 9 mg twice daily, or placebo respectively, with stratification according to back - ground anti-fibrotic therapy (nintedanib or pirfenidone) versus none 5 .”
Dierl, A., Hinsen, M., Wild, E.-M., et al. (2026) · Communications Medicine · doi:10.1038/s43856-025-01365-w
Liu, B., May, J. M., Contento, G., Gangi, S., Organ, L. A., Pyman, E., Kibreab, I., Zhao, L., Yao, H., Chambers, R. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.21.700846
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation AnalysisPreprint
Oldham, J., Molyneaux, P. L., Maddali, M. V., Newton, C. A., Kim, J. S., Konkol, S., Pugashetti, J. V., Liu, G. Y., Goobie, G. C., Adegunsoye, A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8714555/v1
Self-citationFassio, A., Pollastri, F., Appoloni, M., Baltieri, S., Ventura, A., Rossini, M., Carobene, L., Micheletto, C., Adami, G., Sebastiani, M., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03552-2
“Similar effect sizes have been reported in more recent trials such as FIBRONEER-IPF [37] and FIBRONEER-PPF [38].”
Yin, Y., Wu, X., Liu, Z., Luo, Y., Jing, M., Jing, K., Li, Q., Wang, F., & Huang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761899 · Cited by 1
“It significantly improves FVC in IPF patients through a multi-level synergistic mechanism (Richeldi et al., 2025).”
Buccardi, M., Pennati, F., Ferrini, E., Buseghin, D., Polverini, E., Sverzellati, N., Aliverti, A., & Stellari, F. F. (2026) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1093/ajrcmb/aanag036
Management der progredienten Lungenfibrosen – Update 2025
Schlee, T., Kreuter, M., & Krönig, J. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2609-8433
“Bei gleichzeitiger Nintedanib-Therapie traten Diarrhöen bei 49,1% (18mg) und 48% (9mg) im Vergleich zu 36,5% unter Plazebo auf [17, 18].”
Self-citationIdiopathic interstitial lung diseases - treatment options
Šterclová, M. (2026) · Česká a slovenská farmacie · doi:10.36290/csf.2026.003
Cheng, Y., Shan, Y., Zheng, Y., Zhao, F., Shi, Y., Song, C., Li, Y., Zhao, J., Chang, C., Wang, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770348
“It has been reported in a phase 2 trial involving patients with idiopathic pulmonary fi brosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks (68).”
Konoeda, C., Toyokawa, G., Shimokawa, M., & Sato, M. (2026) · Surgery Today · doi:10.1007/s00595-026-03250-y · Cited by 1
“Nerandomilast, a phosphodiesterase 4 B inhibitor with antifibrotic and immu - nomodulatory effects, is also expected to improve immune competence and the inflammatory response [ 25].”
Zaizen, M., Zaizen, Y., Tsumura, K., Chikasue, T., Nagata, S., 誠之, 渡., Okamoto, M., Tominaga, M., Tabata, K., Tanoue, S., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101417
Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote FibrosisPreprint
Li, D., Viñado, A. C., García‐Olloqui, P., Montesi, S. B., Shea, B. S., Christian, L., Vázquez-Urio, I., Aguirre-Ruiz, P., Ariceta, B., Neubert, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.24.710438
“Although antifibrotic therapies modestly slow disease progression 4–6 , IPF remains incurable, and substantial heterogeneity in disease course and therapeutic response persists 1–3 .”
Ghosh, M., Sharma, N., Moulik, S., & Andugulapati, S. B. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117940
Chalmers, J. D., & Daley, C. L. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag096
Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases
Kulkarni, T., Funke-Chambour, M., Jones, S., Rivera‐Ortega, P., & Montesi, S. B. (2026) · Thorax · doi:10.1136/thorax-2024-222057
Treatable traits in interstitial lung disease: towards precision medicine
Avitzur, N., Marinescu, D.-C., Churg, A., Goobie, G. C., Hague, C. J., Müller, N. L., Wright, J. L., & Ryerson, C. J. (2026) · Thorax · doi:10.1136/thorax-2024-222058
Will the anti-fibrotic effects of nerandomi-last? FIBRONEER-IPF part 2
Khor, Y. H., & Jenkins, G. R. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag088
Is there more to change in forced vital capacity in pulmonary fibrosis trials?
Andrei, A., & Kass, D. J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag171
Nanodelivery systems-empowered therapies of idiopathic pulmonary fibrosis
Zhang, M., Jiang, Y., Wu, C., et al. (2026) · Exploration of Medicine · doi:10.37349/emed.2026.1001397
Rossanese, M., & Platé, M. (2026) · Thorax · doi:10.1136/thorax-2026-224844
“9 While welcome, these agents only slow, rather than reverse, disease trajectories, leaving substantial unmet clinical need.”
Bai, Q., Deng, J., Wang, H., Yao, Y., & Wang, T. (2026) · iNew Medicine · doi:10.1002/inm3.70052 · Cited by 1
Luppi, F., & Ferrara, G. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag200
A syndromic framework for progressive pulmonary fibrosis
Perrotta, F., Luppi, F., Sebastiani, M., & Bianco, A. (2026) · Respiratory Research · doi:10.1186/s12931-026-03649-8 · Cited by 1
“In the phase III FIBRONEER-IPF trial, nerandomilast significantly reduced FVC decline at 52 weeks compared with placebo [79].”
Tonelli, R., Turchiano, M. G., Moretti, A., Andrisani, D., Gozzi, F., Raineri, G., Samarelli, A. V., Andolfi, F., Ruggieri, V., Clini, E. M., et al. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04343-9 · Cited by 1
Richie, R. C., & Engman, M. L. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_27-1
Mansour, G. K., Hajjar, A. W., & Sukkarieh, H. H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1748453 · Cited by 1
Xu, H., Meier, E., Chhabria, M., DeDent, A. M., Hui, S. L., Zhang, Z., & Boente, R. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.03.040
Interstitielle Lungenerkrankungen: Feine Unterschiede erkennen, gezielt handeln
von Eiff, D., Herth, F. J. F., & Polke, M. (2026) · Pneumo News · doi:10.1007/s15033-026-4291-7
ERS Congress 2025: highlights from the Interstitial Lung Diseases Assembly
Khoury, J., Yüksel, A., Bizymi, N., Fabozzi, A., Garcia-Moyano, M., Wijsenbeek, M. S., Kreuter, M., & Fabbri, L. (2026) · ERJ Open Research · doi:10.1183/23120541.00344-2026
“Add-on or upfront combination therapies may be on the horizon, as novel antifibrotics such as nerandomilast and treprostinil advance through clinical development [4, 5].”
Self-citationHolistic Management of Pulmonary Fibrosis: A Comprehensive Review
Palacio, I., Hernández‐González, F., Sellarés, J., & Bordas-Martínez, J. (2026) · Medicina · doi:10.3390/medicina62050817 · Cited by 1
“Recent positive trials for nerandomilast and inhaled treprostinil are expanding the antifi-brotic armamentarium beyond pirfenidone and nintedanib, reinforcing the urgency of precision-based approaches to individualized treatment selection [75–77].”
Guo, Y., Wang, X., Zhang, F., Zheng, T., Chen, Z., Wang, S., Yang, G., Wang, H., Yin, W., Huang, S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050516
Drug repurposing for lung disease: mechanistic rationale, clinical evidence, and the path forward
Bhatt, S., Gyimah, C., Kaul, B., Johannson, K. A., LIMPER, A. H., & Dempsey, T. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag216
Highlights des DGP-Kongresses 2026 aus Sicht der YoungDGP
Groth, E. E., Büscher, E., Chaabouni, M., et al. (2026) · Pneumologie · doi:10.1055/a-2845-5938
Zhu, J., Gong, K., Xu, M., Sun, T., Li, Z., Liu, Y., Li, L., Xiao, L., Liu, C., & Zhu, Q. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05384-9 · Cited by 1
Self-citationBeaulé, M. Y., Getachew, L. S., & Sparks, J. A. (2026) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001169 · Cited by 1
Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis
Yue, L., Li, Y., Gan, C., Sun, M., Deng, C., Xue, T., Xie, Y., Liu, H., Liu, Z., & Ye, T. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109945
Xiong, D.-Y., Zhang, C.-Y., Zhang, Y.-F., Zeng, Q., Liu, W. T., Yang, N., Tang, S.-Y., Jia-Hui, Z., Zhou, Y., & Huang, X.-T. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02921-0
“Idiopathic pulmonary fibrosis (IPF) is the most common form of PF, with morbidity and mortality steadily increasing in recent years [2].”
Reading the monocyte code in idiopathic pulmonary fibrosis
Curioni, A. V., Crestani, B., & Helou, D. G. (2026) · European Respiratory Journal · doi:10.1183/13993003.00349-2026
Advances in pharmacotherapy for fibrotic interstitial lung disease
Feng, X., Deng, M., Miao, J., Zheng, Z., & Hou, G. (2026) · Medical Review · doi:10.1515/mr-2025-0086 · Cited by 1
“With the completion of two phase III trials for IPF and PPF (FIBRONEER-IPF and FIBRONEER-ILD, respectively), a marketing application for nerandomilast is now in preparation [87, 88].”
InfluentialXu, J., Liu, X., Liang, X., Cai, X., & Qian, W. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04342-8 · Cited by 2
“Ultimately, 35 publications were included [14–16, 21, 24–54], comprising 42 randomized controlled trials (RCTs) (Fig.”
Collier, J., Bowcutt, R., Johnston, G. I., Chan, J., Raievska, A., Bigley, A. L., Nicholl, R., Schmidt, T., Sarno, M., Ali, Z., et al. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70052 · Cited by 1
“32 35–38 None of these therapies has been shown to stop disease progression in pulmonary fibrosis, nor are they approved for the treatment of kidney fibrosis.”
Liu, W. T., Sun, Y., Zhao, L., Wang, S. Y., Zhou, G. F., Wang, S. Y., Xie, S., Geng, J., Xie, B., Ai, W., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03714-2
“Currently approved therapies, including nintedanib, pirfenidone, and the recently approved phosphodiesterase 4B (PDE4B) inhibitor nerandomilast, can slow disease progression but cannot reverse established fibrosis [7].”
Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling
Tsiri, P., Crestani, B., Mailleux, A., & Tzouvelekis, A. (2026) · Diagnostics · doi:10.3390/diagnostics16101493
“Although antifibrotic therapies such as pirfenidone and nintedanib slow disease progression, and newer agents such as nerandomilast are expanding the therapeutic landscape, these treatments do not reverse established fibrosis [3–5].”
The changing face of lung transplant candidates
Leuzzi, F. R., Clausen, E. S., & Dilling, D. F. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001273
Bui, P., Onge, E. S., Sotolongo-Miranda, H., & Trabulsi, T. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261447319
Huang, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118960
Newton, C. A. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag237
Salvianolic Acid B Inhibited LH2 Expression to Reduce Collagen Synthesis in Pulmonary Fibrosis
Shao, S., Rao, S., Hu, S., Zhang, Y., Zheng, P., Li, C., Zhong, L., Long, Y., Tian, X., Tang, X., et al. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71168
“Their clinical utility is constrained by dose-limiting gastrointestinal, hepatic, and cutaneous adverse events that lead to dose reduction or discontinuation in 20%–30% of patients [4, 35, 36].”
Cao, Z., Wei, S., Zhao, Z., Yue, L., Cui, Y., Xu, S., Tan, Z., & Zhai, X. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00982
When the lung is at risk: diagnosis, manifestations, and complications of pulmonary sarcoidosis
Dhanani, Z., Vorselaars, A. D. M., Gupta, R., & Spagnolo, P. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102792 · Cited by 1
Kølner-Augustson, L., Altraja, A., Bendstrup, E. M., Bradding, P., Østergård, N. M., Wilson, A. C., Simonsen, U., & Hilberg, O. (2026) · Diagnostics · doi:10.3390/diagnostics16111649
“In this respect, the trial differs from previous IPF trials, which did not require documented disease progression before enrolment [5,6,8], and previous progressive F-ILD trials, which accepted progression documented within the preceding 24 months [7,9,10].”
O-GlcNAc transferase regulates H 2 O 2 production via p38 MAPKPreprint
Jones, L., Vang, S., McIntire-Ray, H. J., Petersen, H. A., Morales, A. N., de la Rúa, R., Anderson, J. C., Coba, A. J. G., Krick, S. E., & Barnes, J. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.728188
Pulmonary fibrosis: evolving therapeutic pipeline
Shannon, L., Islam, S., Hilary, B., Murphy, G., Bailey, S., Rooney, R., & Chaudhuri, N. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-001886
Beyond scarring: a next-generation vision for pulmonary fibrosis management
Liu, X., & Li, Z. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12082-5 · Cited by 2
Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution
Lebeaupin, C., Donahue, K. L., Dower, K., Wynn, T. A., Hart, K. M., & Fabre, T. (2026) · JCI Insight · doi:10.1172/jci.insight.200155
“The currently approved therapies for IPF/ILD, nintedanib, pirfenidone, and nerandomilast (153), are complex kinase inhibitors and PDE4B blockers that target growth factor signaling (nintedanib target PDGF, for example, is considered a core fibrogenic pathway) (154).”
CTHRC1: a serum biomarker for a pathological fibroblast in IPF
Khatri, A., & Todd, J. L. (2026) · Thorax · doi:10.1136/thorax-2026-225250
Perspective Chapter: FGF/FGFR Signaling in Disease Pathogenesis
Qi, X., Geng, X., & Wu, H. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015716
Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials
Zhao, C., Song, C., Zhou, Y., Luo, J., Zheng, S., Li, X., Dang, Y., Yang, N., & Kong, J. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04340-w
“Diarrhea was the most common adverse event (41.3% in the 18 mg group), and the incidence of serious adverse events was balanced across groups[38].”
InfluentialAcute Exacerbation of Interstitial Lung Disease: A Case Series and a Narrative Literature Review
Czyżak, B., Lasota, A., & Majewski, S. (2026) · Advances in respiratory medicine · doi:10.3390/arm94030042
“In addition, a trend toward a reduced risk for first AE, respiratory hospitalization, or death was observed (HR, 0.77; 95% CI, 0.59–1.01; p = 0.06), although this result did not reach statistical significance [52,53].”
InfluentialPreclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy
Jordan, M., Stucki-Koch, A., Schinke, M., Willmer, L., Senne, I., Abbas, N., Bentele, M., Oldenkott, D., Lachmann, N., Feldbrügge, L., et al. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02695-5 · Cited by 1
Therapie der idiopathischen Lungenfibrose: Langzeiteffektivität von Nerandomilast
Gillissen, A. (2026) · Pneumo News · doi:10.1007/s15033-026-4323-3
“Der Unterschied zwischen Nerandomilast (18 mg) und Placebo betrug 68,8 ml (p 0,001) und der zwischen Neran-domilast (9 mg) und Placebo 44,9 ml (p=0,02) [3].”
InfluentialRheumatoid arthritis and interstitial lung diseases: modern approaches to therapy
Belov, B. S., Muravyevа, N. V., & Sedelnikova, M. A. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-12-49-56
Chen, D., & Xiang, F. (2026) · Canadian Respiratory Journal · doi:10.1155/carj/6653364
“Nerandomilast, a phosphodiesterase 4B inhibitor, has been shown to slow the decline in lung function in patients with IPF and progressive PF, while exhibiting a relatively favorable safety profle, leading to its approval for the treatment of both IPF and progressive PF [136, 137].”
The Coming Challenge in Interstitial Lung Disease: Choosing the Optimal Therapeutic Strategy
Castro, H. M. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.06.010
Koschel, D., Behr, J., & Bonella, F. (2026) · Pneumologie · doi:10.1055/a-2883-1874
“Die Patientenpopulation bezog sich bei fünf Studien auf die Diagnose IPF [4 – 6,11,14], bei zwei Studien auf die Diagnose PPF [7,13] und bei einer Studie auf die Diagnose SSc-ILD [9].”
Preserving Lung Function in Idiopathic Pulmonary Fibrosis
Taichman, D. B. (2026) · New England Journal of Medicine · doi:10.1056/nejme2606821 · Cited by 2
Inhaled treprostinil and the vascular turn in pulmonary fibrosis
Yanagihara, T., & Kolb, M. R. J. (2026) · Med · doi:10.1016/j.medj.2026.101190
BAIBA attenuates pulmonary fibrosis by modulating the iron/ROS–mitochondrion–apoptosis cascade
Du, C., Wang, J., Wang, X., Tan, K., Wang, B., Chen, J., Luo, B., Xiong, Z., Zhang, Z., Liu, S., et al. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.07.029
Interstitial Lung Disease In Older Adults
Chiang, G. C., Shao, S., & Antin-Ozerkis, D. E. (2026) · Respiratory medicine · doi:10.1007/978-3-032-29861-4_15
Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis
Bishop, K. N., Santana, J. M., Dietrich, E., et al. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261466572
“9 Importantly, rates of serious adverse events and treatment discontinuation were similar to those with placebo in clinical trials, suggesting potentially improved tolerability compared to existing therapies, which are frequently associated with dose reductions and discontinuation.”
Maher, T. M., Assassi, S., Chauffe, A., Barbera, T., Fourtouna, A., & Martínez, F. J. (2026) · Video Journal of Biomedicine · doi:10.1080/26315904.2026.2692050
Self-citationKrueppel-like factors transcriptionally regulate idiopathic pulmonary fibrosis
Bhattacharyya, A., & Syamal, A. K. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101488 · Cited by 1
Perrotta, F., Mariniello, D. F., Pagliaro, R., et al. (2026) · European Respiratory Review · doi:10.1183/16000617.0095-2026
Reccardini, N., Re, B. D., Mondini, L., Salton, F., Confalonieri, M., Confalonieri, P., Hughes, M., Monteleone, G., & Ruaro, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1865787
“In October 2025 the Food and Drug Administration (FDA) approved nerandomilast, an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects (Richeldi et al., 2025).”
Interstitial Lung Disease in the United States: CDC Mortality Trends (1999–2024)
Grover, P., Jain, R., Kaur, G., & Singh, B. (2026) · Advances in respiratory medicine · doi:10.3390/arm94040051
“Individual-level studies and meta-analyses have demonstrated mortality benefits of antifibrotic therapy in patients with IPF [12–15], and more recently, newer therapeutic agents including nerandomilast and pamrevlumab have shown promise in clinical trials [16,17].”
Han, J., Lee, H.-K., Lee, H., Lee, H. Y., Hong, S., & Bang, Y. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04524-4
Pulmonary fibrosis and the TGF-β signaling axis: Advances in targeted therapeutics
Wang, Y., Xu, Y., Zhang, Y., Wang, B., Liu, X., & Zhang, H. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179174 · Cited by 1
Conversations in collagen: multicellular cross talk shapes the fibrotic niche in pulmonary fibrosis
Salamon, R. J., & Saini, S. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00426.2025
Computational Analysis of Fibroblast Subpopulation Dynamics as a Driver of Fibrotic Foci FormationPreprint
Leonard‐Duke, J., Csordas, D. J., Hannan, R. T., Sano, C., Hossainian, D., Batavia, M., Andrews, R., Ambrosone, M., Eggertsen, T. G., Velez, T. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742640
Freund, O., Katsoff, U., Hershko, T., et al. (2026) · Advances in respiratory medicine · doi:10.3390/arm94040057
Pharmacokinetics and Safety of Nerandomilast in Healthy Volunteers
Jappar, D., Wu, J., Burkard, U., Sharma, A., Coeck, C., Zoz, D. F., & Yu, Y. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-026-01027-9
“…subsequently investigated in two large phase III trials over 52 weeks (FIBRONEER TM -IPF [NCT05321069] and FIBRONEER TM -ILD [NCT05321082]), at doses of 9 mg and 18 mg BID, and was shown to significantly reduce the decline in lung function in patients with IPF and PPF at both dose levels [33,34].”
Self-citation
Metadata
- Authors
- Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., Wachtlin, D., Liu, Y., Schlecker, C., Stowasser, S., Zoz, D. F., & Wijsenbeek, M. S.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Nippon Medical School (JP)
- Lyon 1 Université (FR)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University of Southern California (US)
- University of Massachusetts (UMass) Chan Medical School–UMass Memorial Health System, Worcester
- University of Michigan (US)
- Hospital Universitario de La Princesa (ES)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (France) (FR)
- Boehringer Ingelheim (United States) (US)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-12
- Volume
- 392
- Issue
- 22
- Pages
- 2193-2202
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410472815
- Cited by
- 297
- References
- 20
- Citations by year
- 2026: 231 · 2025: 65
- FWCI
- 175.62
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- nerandomilast, idiopathic pulmonary fibrosis, antifibrotic therapy, nintedanib, pirfenidone, forced vital capacity, lung function, dose comparison, diarrhea, adverse events, antifibrotic agents, immunomodulatory therapy, antiproliferative therapy
- MeSH terms
- Antifibrotic Agents, Administration, Oral, Aged, Cyclobutanes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles, Lung, Male, Middle Aged, Organic Chemicals, Piperidines, Pyridones, Tablets, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis, Phosphodiesterase 4 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.